摘要
心力衰竭治疗策略几经变迁,治疗目标从抑制肾素-血管紧张素-醛固酮系统和交感神经系统激活转变为平衡神经内分泌系统失调。沙库巴曲缬沙坦是一种具有抑制脑啡肽酶和阻滞血管紧张素受体双重作用的新型药物,可显著降低射血分数降低性心力衰竭患者的病死率,改善患者预后。本文阐述沙库巴曲缬沙坦治疗心力衰竭的作用机制、研究进展及药物安全性,以指导临床应用。
Treatment strategies for heart failure have changed over the past decades,and currently the treatment target shifts from suppressing the renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS) to balancing neuroendocrine dysregulation.Sacubitril/Valsartan is a new drug for heart failure which inhibits both enkephalin and angiotensin receptors.Sacubitril/Valsartan significantly reduce the mortality of heart failure with reduced ejection fractions and improve the patient outcomes.The mechanism,research progress and safety issue of Sacubitril/Valsartan in the treatment of heart failure are summarized in this review to guide its clinical application practice.
作者
张小红
薛竟宜
李俭强
李为民
ZHANG Xiaohong;XUE Jingyi;LI Jianqiang;LI Weimin(Department of Cardiology,The First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150001, China)
出处
《临床心血管病杂志》
CAS
CSCD
北大核心
2018年第12期1215-1218,共4页
Journal of Clinical Cardiology
关键词
沙库巴曲缬沙坦
心力衰竭
利钠肽系统
Sacubitril/Valsartan
heart failure
natriuretic peptides system
